Singapore, Aug 6, 2010: The Spanish Bioindustry Association (ASEBIO) in collaboration with the Navarre Society of Development (SODENA), and the Government of Navarre, will host BioSpain 2010, the biennial international gathering of experts in the biotechnology sector, in Pamplona from Sep 29 to Oct 1.

Mr Carlos Cordón-Cardo, Vice-Chair of Pathology & Professor, Columbia University; Mr. Larry Fritz, President & CEO, Covella Pharmaceuticals Inc. and Life Science Venture Partner, Westfield Capital Management Company LP; and Mr. Conny Bogentoft, CEO, Karolinska Development AB are the keynote speakers
 
 
Over 160 companies are participating in this year's  BioSpain, a 33% increase on BioSpain 2008. Over 1,200 delegates from 650 companies and institutions are  expected to attend.
 
 
BioSpain 2010 will feature an extensive program of breakout sessions addressing the most relevant topics in the current biotech scenario, including: 
 
Bioenergy
Orphan Drugs & Rare Diseases
Alzheimer’s and other neurodegenerative diseases: “What is the Spanish industry doing to develop new drugs?”
Protein Production & Biosimilars
Bioinformatics solutions for genomics: from sequences to Biotechnology and Biomedicine
Alternative Equity Market for Growth Companies
Venture Capital
Biotech’s Next Big Thing?
Joint Technology Cooperation Projects between Spain and other countries: Eureka & Canadeka
International Technology Commercialization: The Challenges of US-European Public-Private Partnerships.  
 
BioSpain 2010 will have the regular feature,  the scientific conference organised by the Spanish Society of Biotechnology (SEBIOT), Biotec 2010.
 
The highlight of the conference is an international round-table discussion on the present state of the biotechnological industry, its development and future proscpects, called “Opportunities and Challenges in Global Biomarkets”. 

A significant part of the conference is the , the investors’ forum that seeks to find new financing sources for future entrepreneurial projects. 30 companies will present their business plan to an audience of experts and investors, including representatives of Merck & Co, Bay City Capital, La Caixa, Ysios Capital Partners, GlaxoSmithKline Pharmaceuticals, Forbion Capital Partners, Suanfarma Biotech, McKinsey & Company, and PharmaVentures.
 
Official sponsors of BioSpain 2010 include Caja de Navarra, The Zeltia Group, Genoma España, AB Biotics, Genetrix, Merck, and ICEX.